Previous 10 | Next 10 |
Akcea Therapeutics (NASDAQ: AKCA) and Ionis Pharmaceuticals (NASDAQ: IONS) announced on Tuesday the results for a phase 2 trial featuring AKCEA-ANGPTL3- L Rx , a drug candidate developed to combat hypertriglyceridemia. Patients with non-alcoholic fatty liver disease, type 2 diabetes, and...
Akcea Therapeutics (NASDAQ: AKCA ) and majority owner Ionis Pharmaceuticals (NASDAQ: IONS ) announce positive results from a Phase 2 clinical trial evaluating antisense oligonucleotide AKCEA-ANGPTL3-L Rx in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty...
Favorable safety and tolerability were observed P rimary and multiple secondary endpoints were met with significant reduction in triglyceride levels, additional lipid parameters and ANGPTL3 BOSTON and CARLSBAD, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NA...
Ionis Pharmaceuticals ( IONS ) and its majority-owned spinoff Akcea Therapeutics ( AKCA ) work together on RNA-based therapies for a wide spectrum of diseases. On January 22, 2020, they announced that the potential therapy AKCEA-APOCIII-LRx for hypertriglyceridemia (high triglycerides in the b...
Akcea Therapeutics (NASDAQ: AKCA) and Ionis Pharmaceuticals (NASDAQ: IONS) reported positive results from a phase 2 clinical trial testing AKCEA-APOCIII-Lrx in patients with high triglyceride levels who either have cardiovascular disease or are at high risk for developing it. The results...
One Stop Systems (NASDAQ: OSS ) +56% reports prelim results . More news on: One Stop Systems, Inc., Genprex, Inc., Akcea Therapeutics, Inc., Stocks on the move, Read more ...
Akcea Therapeutics (NASDAQ: AKCA ) and majority owner Ionis Pharmaceuticals (NASDAQ: IONS ) announce positive results from a Phase 2 clinical trial evaluating antisense drug AKCEA-APOCIII-L Rx in patients with elevated triglycerides in their blood who are at risk for or have e...
BOSTON and CARLSBAD, Calif. , Jan. 22, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive topline results from the Phase 2 study of AKCEA-APOCII...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Investing in biotech stocks can seem like a speculative gamble on binary outcomes, sort of like buying lottery tickets. Fortunately, there are some mid-cap biotechs actually making a profit and that have development pipelines stocked with drug candidates that could produce big winners, giving pa...
News, Short Squeeze, Breakout and More Instantly...
Akcea Therapeutics Inc. Company Name:
AKCA Stock Symbol:
NASDAQ Market:
Akcea Therapeutics Inc. Website:
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire BOSTON and CARLSBAD, Calif., Oct. 30, 2020 BOSTON and CARLSBAD, Calif. , Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, In...
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire CARLSBAD, Calif., Oct. 12, 2020 CARLSBAD, Calif. , Oct. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS...
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA ), relating...